Ozlem Ozer Cakir1, Aysun Toker2, Huseyin Ataseven3, Ali Demir3, Hakki Polat3. 1. Associate Professor, Department of Gastroenterology and Hepatology, Konya Education and Research Hospital, Konya, Meram, Turkey. 2. Associate Professor, Department of Biochemistry, Necmettin Erbakan University, Meram School of Medicine, Konya, Meram, Turkey. 3. Professor, Department of Gastroenterology and Hepatology, Necmettin Erbakan University, Meram School of Medicine, Konya, Meram, Turkey.
Abstract
INTRODUCTION: Acute hepatitis is acute inflammation of liver elicited by a large number of causes. It sometimes spontaneously recovers, sometimes may progress to chronic hepatitis. Liver- Fatty Acid Binding Protein (L-FABP) is a small protein that is abundant in hepatocytes, and which binds most of the long-chain fatty acids present in the cytosol. AIM: The present study was aimed to investigate the levels of serum and urine L-FABP in acute hepatitis and diagnostic value of serum and urine L-FABP levels in patients with acute hepatitis. MATERIALS AND METHODS: The present study included a total of 85 patients. Total number of patients with acute hepatitis were 17 (five of acute hepatitis B, one of acute hepatitis A, two of acute hepatitis C, five of autoimmune hepatitis and four of toxic hepatitis), 19 of hepatic encephalopathy, 29 of liver cirrhosis, and 20 controls were included. Serum and urinary L-FABP levels were analyzed by the Enzyme-Linked Immunosorbent Assay (ELISA). RESULTS: Serum L-FABP levels were 9110±3352.5, 9410±1355, 9715±2462 and 3672±982.5 ng/l in patients with acute hepatitis, hepatic encephalopathy and cirrhosis and control subjects, respectively. There were statistically significant positive correlations between serum levels of L-FABP and Aspartate Aminotransferases (AST), Alanine Aminotransferases (ALT), Creatinine (Cre) and Gamma Glutamyl Transferases (GGT) (p<0.001, p<0.001, p<0.001 and p<0.001, respectively). While the cut-off value of serum L-FABP for all of the patients was 5183 ng/l {p<0.001 and Area Under Curve (AUC) 0.985}, the sensitivity and specificity were 95.4% and 100%, respectively. Positive and negative predictive values for serum L-FABP were 100% and 87%, respectively. CONCLUSION: Serum and urine L-FABP may be a new diagnostic marker for liver damage in patients with acute hepatitis. However, our study showed that except of aminotransferases, L-FABP should be used for diagnosis of liver damage in patients with acute hepatitis, chronic hepatitis and also cirrhosis.
INTRODUCTION:Acute hepatitis is acute inflammation of liver elicited by a large number of causes. It sometimes spontaneously recovers, sometimes may progress to chronic hepatitis. Liver- Fatty Acid Binding Protein (L-FABP) is a small protein that is abundant in hepatocytes, and which binds most of the long-chain fatty acids present in the cytosol. AIM: The present study was aimed to investigate the levels of serum and urine L-FABP in acute hepatitis and diagnostic value of serum and urine L-FABP levels in patients with acute hepatitis. MATERIALS AND METHODS: The present study included a total of 85 patients. Total number of patients with acute hepatitis were 17 (five of acute hepatitis B, one of acute hepatitis A, two of acute hepatitis C, five of autoimmune hepatitis and four of toxic hepatitis), 19 of hepatic encephalopathy, 29 of liver cirrhosis, and 20 controls were included. Serum and urinary L-FABP levels were analyzed by the Enzyme-Linked Immunosorbent Assay (ELISA). RESULTS: Serum L-FABP levels were 9110±3352.5, 9410±1355, 9715±2462 and 3672±982.5 ng/l in patients with acute hepatitis, hepatic encephalopathy and cirrhosis and control subjects, respectively. There were statistically significant positive correlations between serum levels of L-FABP and Aspartate Aminotransferases (AST), Alanine Aminotransferases (ALT), Creatinine (Cre) and Gamma Glutamyl Transferases (GGT) (p<0.001, p<0.001, p<0.001 and p<0.001, respectively). While the cut-off value of serum L-FABP for all of the patients was 5183 ng/l {p<0.001 and Area Under Curve (AUC) 0.985}, the sensitivity and specificity were 95.4% and 100%, respectively. Positive and negative predictive values for serum L-FABP were 100% and 87%, respectively. CONCLUSION: Serum and urine L-FABP may be a new diagnostic marker for liver damage in patients with acute hepatitis. However, our study showed that except of aminotransferases, L-FABP should be used for diagnosis of liver damage in patients with acute hepatitis, chronic hepatitis and also cirrhosis.
Authors: Maurice M A L Pelsers; Alireza Morovat; Graeme J M Alexander; Wim T Hermens; Andrew K Trull; Jan F C Glatz Journal: Clin Chem Date: 2002-11 Impact factor: 8.327
Authors: D Monbaliu; B de Vries; T Crabbé; E van Heurn; C Verwaest; T Roskams; J Fevery; J Pirenne; W A Buurman Journal: Transplant Proc Date: 2005 Jan-Feb Impact factor: 1.066
Authors: Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein Journal: Nat Rev Gastroenterol Hepatol Date: 2013-08-20 Impact factor: 46.802
Authors: Maartje A J van den Broek; Johanne G Bloemen; Simon A W G Dello; Marcel C G van de Poll; Steven W M Olde Damink; Cornelis H C Dejong Journal: J Hepatol Date: 2010-12-13 Impact factor: 25.083
Authors: Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei Journal: Hepatology Date: 2002-03 Impact factor: 17.425
Authors: Maartje A J van den Broek; Ronit Shiri-Sverdlov; Joris J W Schreurs; Johanne G Bloemen; Veerle Bieghs; Sander S Rensen; Cornelis H C Dejong; Steven W M Olde Damink Journal: Liver Int Date: 2013-01-29 Impact factor: 5.828
Authors: Rachel G Khadaroo; Spyridon Fortis; Saad Y Salim; Catherine Streutker; Thomas A Churchill; Haibo Zhang Journal: PLoS One Date: 2014-12-26 Impact factor: 3.240
Authors: José M Yáñez; Grazyella M Yoshida; Ángel Parra; Katharina Correa; Agustín Barría; Liane N Bassini; Kris A Christensen; Maria E López; Roberto Carvalheiro; Jean P Lhorente; Rodrigo Pulgar Journal: Front Genet Date: 2019-08-05 Impact factor: 4.599
Authors: Ricardo O S Soares; Daniele M Losada; Maria C Jordani; Paulo Évora; Orlando Castro-E-Silva Journal: Int J Mol Sci Date: 2019-10-11 Impact factor: 5.923